Consistent with previous findings for bladder urothelial carcinoma, breast invasive carcinoma, colon adenocarcinoma and prostate adenocarcinoma, PHLPP2 levels were significantly lower in the tumor tissues than those in non‐tumor tissues (Fig 1a). This evidence concerns the gene PHLPP2 and invasive breast carcinoma.